|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| C12P 21/08 | (2006.01) | ||
| G01N 33/574 | (2006.01) | ||
| C07K 16/28 | (2006.01) |
| (11) | Number of the document | 3290052 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17191118.3 |
| Date of filing the European patent application | 2009-11-06 | |
| (97) | Date of publication of the European application | 2018-03-07 |
| (45) | Date of publication and mention of the grant of the patent | 2019-12-25 |
| (46) | Date of publication of the claims translation | 2020-02-25 |
| (30) | Number | Date | Country code |
| 112686 P | 2008-11-07 | US | |
| 164870 P | 2009-03-30 | US |
| (72) |
KYUNG JIN, Kim, US
ZHAO, Wei-Meng, US
PARK, Hangil, US
|
| (73) |
Galaxy Biotech, LLC,
22830 San Juan Road, Cupertino CA 95014,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Monokloniniai antikūnai fibroblastų augimo faktoriaus receptoriui 2 |
| MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2 |
| Payment date | Validity (years) | Amount | |
| 2024-10-22 | 16 | 347.00 EUR |
| 2025-11-06 |